Novo Nordisk (NYSE: NVO) CEO Mike Doustdar said the company will accelerate research and development and pursue more bolt-on acquisitions following recent clinical setbacks. The strategy comes after another disappointment for CagriSema and weaker-than-expected sales of the oral Wegovy pill, despite the company raising its 2026 financial outlook. Sector: Pharmaceuticals Key Highlights 🧪 CEO plans to accelerate R&D with "more shots at goal" 🤝 Company intends to pursue more bolt-on acquisitions ⚠️ Strategy follows another CagriSema clinical setback 💊 Oral Wegovy sales came in below expectations 📈 Novo Nordisk still raised its 2026 outlook Why It Matters Novo Nordisk is responding to recent pipeline challenges by accelerating innovation and expanding through targeted acquisitions, aiming to strengthen its long-term growth and leadership in the obesity and diabetes markets. Read More: https://www.thinksabio.com/reports/isr/NVO